Daiwa Securities Group Inc. Has $92,000 Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Daiwa Securities Group Inc. reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 11.9% in the 4th quarter, Holdings Channel reports. The firm owned 1,465 shares of the company’s stock after selling 198 shares during the period. Daiwa Securities Group Inc.’s holdings in CRISPR Therapeutics were worth $92,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of CRSP. CWM LLC lifted its holdings in shares of CRISPR Therapeutics by 80.7% during the third quarter. CWM LLC now owns 582 shares of the company’s stock worth $26,000 after buying an additional 260 shares during the last quarter. Tradewinds Capital Management LLC lifted its holdings in shares of CRISPR Therapeutics by 545.5% during the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock worth $32,000 after buying an additional 600 shares during the last quarter. Blue Trust Inc. acquired a new position in shares of CRISPR Therapeutics during the fourth quarter worth approximately $32,000. Headlands Technologies LLC acquired a new position in shares of CRISPR Therapeutics during the third quarter worth approximately $34,000. Finally, Bourgeon Capital Management LLC lifted its holdings in shares of CRISPR Therapeutics by 1,000.0% during the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after buying an additional 500 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $53.91 on Friday. The business’s fifty day moving average price is $70.57 and its two-hundred day moving average price is $63.95. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The stock has a market capitalization of $4.58 billion, a price-to-earnings ratio of -27.50 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million during the quarter, compared to the consensus estimate of $148.72 million. During the same quarter last year, the company earned ($1.41) earnings per share. The business’s revenue was up 3253.3% on a year-over-year basis. Research analysts expect that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 50,000 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the sale, the chief executive officer now owns 187,377 shares in the company, valued at $11,338,182.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, General Counsel James R. Kasinger sold 1,913 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now owns 57,371 shares in the company, valued at $4,570,747.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 50,000 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $60.51, for a total value of $3,025,500.00. Following the sale, the chief executive officer now owns 187,377 shares in the company, valued at approximately $11,338,182.27. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 133,992 shares of company stock worth $9,157,835. Insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CRSP. Royal Bank of Canada upped their price target on CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a report on Thursday, February 22nd. Wells Fargo & Company upped their target price on CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, February 22nd. Wolfe Research assumed coverage on CRISPR Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating for the company. Citigroup upped their target price on CRISPR Therapeutics from $88.00 to $89.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. Finally, Chardan Capital upped their target price on CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $76.29.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.